FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Vaccine2010; 28(39); 6505-6517; doi: 10.1016/j.vaccine.2010.06.105

In vivo cross-protection to African horse sickness Serotypes 5 and 9 after vaccination with Serotypes 8 and 6.

Abstract: The polyvalent African horsesickness (AHS) attenuated live virus (AHS-ALV) vaccine produced at Onderstepoort Biological Products incorporates 7 of the 9 known serotypes circulating in southern Africa. Serological cross-reaction has been shown in vitro to Serotypes 5 and 9 by Serotypes 8 and 6 respectively, but the degree of in vivo cross-protection between these serotypes in vaccinated horses has not previously been reported. Due to the increasing incidence of AHS Serotypes 5 and 9 in the field, over the last 3-4 seasons of AHS in South Africa, and the absence of Serotypes 5 and 9 in the AHS-ALV vaccine, it was necessary to conduct a vaccination-challenge study to determine in vivo cross-protection of vaccine-incorporated Serotypes 8 and 6 respectively. Groups of horses were vaccinated with either the polyvalent AHS-ALV vaccine or a monovalent Serotype 6 (vAHSV6) or 8 (vAHSV8) vaccine to determine the cross-protection of vaccinated horses following challenge with virulent AHS virus (AHSV) of either Serotype 5, 6, 8 or 9. Serial vaccination of naive horses with the polyvalent AHS-ALV vaccine generated a broad neutralizing antibody response to all vaccine strains as well as cross-neutralizing antibodies to Serotypes 5 and 9. Booster vaccination of horses with monovalent vaccine vAHSV6 or vAHSV8 induced an adequate protective immune response to challenge with homologous and heterologous virulent virus. In vivo cross-protection between AHSV6 and AHSV9 and AHSV8 and AHSV5 respectively, was demonstrated.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Get Full Text
Publication Date: 2010-07-16 PubMed ID: 20638456DOI: 10.1016/j.vaccine.2010.06.105Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Randomized Controlled Trial

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research paper focuses on the study of how effective the African Horse Sickness (AHS) live attenuated virus vaccine is, particularly with regards to cross-protection between different serotypes of the disease.

Importance of Research

  • The research is particularly important due to the increased incidence of African Horse Sickness caused by serotypes 5 and 9 in recent years, despite these serotypes not being included in the AHS live attenuated virus vaccine.
  • To address this, the researchers conducted a vaccination-challenge study to determine if there was in vivo (within the body) cross-protection from serotypes 6 and 8, which are included in the vaccine, against serotypes 5 and 9.

Method and Procedures

  • The researchers divided horses into groups and vaccinated them with either the AHS-ALV polyvalent vaccine (which contains multiple serotypes) or a monovalent vaccine (which contains only one serotype) for either serotype 6 or 8.
  • After vaccination, the horses were then challenged with the virulent AHS virus of either serotype 5, 6, 8, or 9 to test the amount of protective immune response generated by the vaccinations.

Results

  • The study found that the AHS-ALV vaccine was able to produce a broad neutralizing antibody response to all serotypes included in the vaccine.
  • In addition, it generated cross-neutralizing antibodies to serotypes 5 and 9, which are not included in the vaccine. This demonstrates that in vivo cross-protection against these serotypes is possible from vaccination with serotypes 6 and 8.
  • The booster vaccinations with the monovalent vaccines also successfully raised adequate immune responses to the challenge with the virulent virus, whether the challenge was with a homologous (same) or heterologous (different) serotype.
  • This again suggests the possibility of cross-protection between serotypes 6 and 9 and between serotypes 8 and 5.

Conclusion

  • The paper concludes that, in vivo cross-protection was demonstrated between serotypes 6 and 8 against serotypes 5 and 9 respectively.
  • This is an encouraging result, suggesting that existing vaccines may still provide protection against these serotypes despite them not being directly included in the vaccine.

Cite This Article

APA
von Teichman BF, Dungu B, Smit TK. (2010). In vivo cross-protection to African horse sickness Serotypes 5 and 9 after vaccination with Serotypes 8 and 6. Vaccine, 28(39), 6505-6517. https://doi.org/10.1016/j.vaccine.2010.06.105

Publication

Vaccine
ISSN: 1873-2518
NlmUniqueID: 8406899
Country: Netherlands
Language: English
Volume: 28
Issue: 39
Pages: 6505-6517

Researcher Affiliations

von Teichman, Beate F
  • Research and Development Virology, Onderstepoort Biological Products Ltd, Private Bag X07, Onderstepoort 0110, South Africa. beate@obpvaccines.co.za
Dungu, Baptiste
    Smit, Theresa K

      MeSH Terms

      • African Horse Sickness / prevention & control
      • African Horse Sickness Virus / classification
      • African Horse Sickness Virus / immunology
      • Animals
      • Antibodies, Neutralizing / blood
      • Antibodies, Viral / blood
      • Body Temperature
      • Cross Protection
      • Horses / immunology
      • Viral Vaccines / immunology

      Citations

      This article has been cited 23 times.
      1. Pitchers KG, Boakye OD, Campeotto I, Daly JM. The Potential of Plant-Produced Virus-like Particle Vaccines for African Horse Sickness and Other Equine Orbiviruses. Pathogens 2024 May 28;13(6).
        doi: 10.3390/pathogens13060458pubmed: 38921755google scholar: lookup
      2. O'Kennedy MM, Roth R, Ebersohn K, du Plessis LH, Mamputha S, Rutkowska DA, du Preez I, Verschoor JA, Lemmer Y. Immunogenic profile of a plant-produced nonavalent African horse sickness viral protein 2 (VP2) vaccine in IFNAR-/- mice. PLoS One 2024;19(4):e0301340.
        doi: 10.1371/journal.pone.0301340pubmed: 38625924google scholar: lookup
      3. Villalba R, Tena-Tomás C, Ruano MJ, Valero-Lorenzo M, López-Herranz A, Cano-Gómez C, Agüero M. Development and Validation of Three Triplex Real-Time RT-PCR Assays for Typing African Horse Sickness Virus: Utility for Disease Control and Other Laboratory Applications. Viruses 2024 Mar 20;16(3).
        doi: 10.3390/v16030470pubmed: 38543834google scholar: lookup
      4. de Klerk JN, Gorsich EE, Grewar JD, Atkins BD, Tennant WSD, Labuschagne K, Tildesley MJ. Modelling African horse sickness emergence and transmission in the South African control area using a deterministic metapopulation approach. PLoS Comput Biol 2023 Sep;19(9):e1011448.
        doi: 10.1371/journal.pcbi.1011448pubmed: 37672554google scholar: lookup
      5. Wang Y, Ong J, Ng OW, Songkasupa T, Koh EY, Wong JPS, Puangjinda K, Fernandez CJ, Huangfu T, Ng LC, Chang SF, Yap HH. Development of Differentiating Infected from Vaccinated Animals (DIVA) Real-Time PCR for African Horse Sickness Virus Serotype 1. Emerg Infect Dis 2022 Dec;28(12):2446-2454.
        doi: 10.3201/eid2812.220594pubmed: 36417933google scholar: lookup
      6. Durán-Ferrer M, Villalba R, Fernández-Pacheco P, Tena-Tomás C, Jiménez-Clavero MÁ, Bouzada JA, Ruano MJ, Fernández-Pinero J, Arias M, Castillo-Olivares J, Agüero M. Clinical, Virological and Immunological Responses after Experimental Infection with African Horse Sickness Virus Serotype 9 in Immunologically Naïve and Vaccinated Horses. Viruses 2022 Jul 15;14(7).
        doi: 10.3390/v14071545pubmed: 35891525google scholar: lookup
      7. Fairbanks EL, Brennan ML, Mertens PPC, Tildesley MJ, Daly JM. Re-parameterization of a mathematical model of African horse sickness virus using data from a systematic literature search. Transbound Emerg Dis 2022 Jul;69(4):e671-e681.
        doi: 10.1111/tbed.14420pubmed: 34921513google scholar: lookup
      8. Calvo-Pinilla E, Marín-López A, Utrilla-Trigo S, Jiménez-Cabello L, Ortego J. Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design. Curr Opin Virol 2020 Oct;44:49-56.
        doi: 10.1016/j.coviro.2020.06.003pubmed: 32659516google scholar: lookup
      9. Molini U, Zaccaria G, Kandiwa E, Mushonga B, Khaiseb S, Ntahonshikira C, Chiwome B, Baines I, Madzingira O, Savini G, D'Alterio N. Seroprevalence of African horse sickness in selected donkey populations in Namibia. Vet World 2020 May;13(5):1005-1009.
        doi: 10.14202/vetworld.2020.1005-1009pubmed: 32636601google scholar: lookup
      10. Monath TP, Kortekaas J, Watts DM, Christofferson RC, Desiree LaBeaud A, Gowen B, Peters CJ, Smith DR, Swanepoel R, Morrill JC, Ksiazek TG, Pittman PR, Bird BH, Bettinger G. Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile. Vaccine X 2020 Aug 7;5:100060.
        doi: 10.1016/j.jvacx.2020.100060pubmed: 32337506google scholar: lookup
      11. Rutkowska DA, Mokoena NB, Tsekoa TL, Dibakwane VS, O'Kennedy MM. Plant-produced chimeric virus-like particles - a new generation vaccine against African horse sickness. BMC Vet Res 2019 Dec 3;15(1):432.
        doi: 10.1186/s12917-019-2184-2pubmed: 31796116google scholar: lookup
      12. Dennis SJ, Meyers AE, Hitzeroth II, Rybicki EP. African Horse Sickness: A Review of Current Understanding and Vaccine Development. Viruses 2019 Sep 11;11(9).
        doi: 10.3390/v11090844pubmed: 31514299google scholar: lookup
      13. Ngoveni HG, van Schalkwyk A, Koekemoer JJO. Evidence of Intragenic Recombination in African Horse Sickness Virus. Viruses 2019 Jul 18;11(7).
        doi: 10.3390/v11070654pubmed: 31323749google scholar: lookup
      14. Aksular M, Calvo-Pinilla E, Marín-López A, Ortego J, Chambers AC, King LA, Castillo-Olivares J. A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model. Vaccine 2018 Nov 12;36(46):7003-7010.
        doi: 10.1016/j.vaccine.2018.09.065pubmed: 30309744google scholar: lookup
      15. Dennis SJ, O'Kennedy MM, Rutkowska D, Tsekoa T, Lourens CW, Hitzeroth II, Meyers AE, Rybicki EP. Safety and immunogenicity of plant-produced African horse sickness virus-like particles in horses. Vet Res 2018 Oct 11;49(1):105.
        doi: 10.1186/s13567-018-0600-4pubmed: 30309390google scholar: lookup
      16. Dennis SJ, Meyers AE, Guthrie AJ, Hitzeroth II, Rybicki EP. Immunogenicity of plant-produced African horse sickness virus-like particles: implications for a novel vaccine. Plant Biotechnol J 2018 Feb;16(2):442-450.
        doi: 10.1111/pbi.12783pubmed: 28650085google scholar: lookup
      17. Weyer CT, Grewar JD, Burger P, Rossouw E, Lourens C, Joone C, le Grange M, Coetzee P, Venter E, Martin DP, MacLachlan NJ, Guthrie AJ. African Horse Sickness Caused by Genome Reassortment and Reversion to Virulence of Live, Attenuated Vaccine Viruses, South Africa, 2004-2014. Emerg Infect Dis 2016 Dec;22(12):2087-2096.
        doi: 10.3201/eid2212.160718pubmed: 27442883google scholar: lookup
      18. Guthrie AJ, Coetzee P, Martin DP, Lourens CW, Venter EH, Weyer CT, Joone C, le Grange M, Harper CK, Howell PG, MacLachlan NJ. Complete Genome Sequences of Four African Horse Sickness Virus Strains from a Commercial Tetravalent Live Attenuated Vaccine. Genome Announc 2015 Nov 25;3(6).
        doi: 10.1128/genomeA.01375-15pubmed: 26607890google scholar: lookup
      19. Guthrie AJ, Coetzee P, Martin DP, Lourens CW, Venter EH, Weyer CT, Joone C, le Grange M, Harper CK, Howell PG, MacLachlan NJ. Complete Genome Sequences of the Three African Horse Sickness Virus Strains from a Commercial Trivalent Live Attenuated Vaccine. Genome Announc 2015 Aug 20;3(4).
        doi: 10.1128/genomeA.00814-15pubmed: 26294618google scholar: lookup
      20. Kanai Y, van Rijn PA, Maris-Veldhuis M, Kaname Y, Athmaram TN, Roy P. Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus. Vaccine 2014 Sep 3;32(39):4932-7.
        doi: 10.1016/j.vaccine.2014.07.031pubmed: 25045805google scholar: lookup
      21. Alberca B, Bachanek-Bankowska K, Cabana M, Calvo-Pinilla E, Viaplana E, Frost L, Gubbins S, Urniza A, Mertens P, Castillo-Olivares J. Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge. Vaccine 2014 Jun 17;32(29):3670-4.
        doi: 10.1016/j.vaccine.2014.04.036pubmed: 24837765google scholar: lookup
      22. Bachanek-Bankowska K, Maan S, Castillo-Olivares J, Manning NM, Maan NS, Potgieter AC, Di Nardo A, Sutton G, Batten C, Mertens PP. Real time RT-PCR assays for detection and typing of African horse sickness virus. PLoS One 2014;9(4):e93758.
        doi: 10.1371/journal.pone.0093758pubmed: 24721971google scholar: lookup
      23. de la Poza F, Calvo-Pinilla E, López-Gil E, Marín-López A, Mateos F, Castillo-Olivares J, Lorenzo G, Ortego J. Ns1 is a key protein in the vaccine composition to protect Ifnar(-/-) mice against infection with multiple serotypes of African horse sickness virus. PLoS One 2013;8(7):e70197.
        doi: 10.1371/journal.pone.0070197pubmed: 23894615google scholar: lookup
      Subscribe to our newsletter
      Join 99,727 horse owners like you who receive our email updates on horse health and nutrition.